Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avatrombopag - Swedish Orphan Biovitrum

Drug Profile

Avatrombopag - Swedish Orphan Biovitrum

Alternative Names: AKR-501; AKR-501 monomaleate; Avatrombopag maleate; DOPTELET; E-5501; YM-477

Latest Information Update: 05 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals; Eisai Co Ltd; Swedish Orphan Biovitrum
  • Class Antithrombotics; Piperazines; Piperidines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombocytopenia; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Registered Idiopathic thrombocytopenic purpura

Most Recent Events

  • 22 Oct 2021 Dova Pharmaceuticals withdraws a phase III trial prior to enrolment in Thrombocytopenia due to corporate decision(NCT05046327)
  • 12 Mar 2021 Phase-III clinical trials in Thrombocytopenia (In infants, In children, In adolescents) in United Kingdom, Russia (PO) (NCT04516967) (EudraCT2020-003232-24)
  • 14 Feb 2021 Phase-III clinical trials in Thrombocytopenia (In children, In adolescents, In infants) in USA (PO) (NCT04516967) (EudraCT2020-003232-24)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top